Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in Transplant Eligible, Higher Risk MDS
NCT03572764Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2018
- Primary completion
- Nov 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daunorubicin + cytarabine liposome in myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Primary endpoint: Safety and tolerability of a CPX-351 regimen at 56 days. Started Dec 2018; status: active, not recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03572764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572764.